IP Library › Granted Patent US 11,608,498
Granted Patent B2
US 11,608,498 · App. 17/963,749 · Granted Mar 21, 2023

Nucleic acid library methods

Inventors: Caroline Julie Gallant (Stockholm, SE); Marlon Stoeckius (Stockholm, SE); Katherine Pfeiffer (San Francisco, CA)
Assignee: 10x Genomics, Inc.
C12N15/1093C12Q1/6837C12Q1/6874
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,608,498
App. No.
17/963,749
Filed
Oct 11, 2022
Granted
Mar 21, 2023
Kind
B2
Art Unit
1637
USPC
435/6.11
Abstract

Provided herein are methods, compositions, and kits for removing a portion of a sequence in a member of a nucleic acid library.

Claims (52)

1. A method for removing all or a portion of a nucleic acid analyte sequence from a double-stranded member of a nucleic acid library, wherein a single strand of the double-stranded member of the nucleic acid library comprises: a first adapter, a barcode, a capture domain, a sequence that is complementary to all or a portion of the nucleic acid analyte sequence, and a second adapter, wherein the method comprises:

(a) ligating to each end of the double-stranded member of the nucleic acid library a first restriction endonuclease recognition sequence;

(b) contacting the double-stranded member of the nucleic acid library of step (a) with a first restriction endonuclease that cleaves the first restriction endonuclease recognition sequence at each end of the double-stranded member of the nucleic acid library;

(c) ligating the ends of the double-stranded member of the nucleic acid library of step (b) to generate a first double-stranded circularized nucleic acid;

(d) amplifying the first double-stranded circularized nucleic acid using a first primer and a second primer to generate a first double-stranded nucleic acid product comprising a second restriction endonuclease recognition sequence at each end of the first double-stranded nucleic acid product, wherein:

the first primer comprises: (i) a sequence substantially complementary to a 3′ region of the nucleic acid analyte sequence and (ii) the second restriction endonuclease recognition sequence; and

the second primer comprises: (i) a sequence substantially complementary to a 5′ region of the nucleic acid analyte sequence, and (ii) the second restriction endonuclease recognition sequence;

(e) contacting the first double-stranded nucleic acid product with a second restriction endonuclease that cleaves the second restriction endonuclease recognition sequence at each end of the first double-stranded nucleic acid product;

(f) ligating the ends of the first double-stranded nucleic acid product of step (e) to generate a second double-stranded circularized nucleic acid; and

(g) amplifying the second double-stranded circularized nucleic acid using a third primer comprising a sequence that is substantially complementary to the first adapter and a fourth primer comprising a sequence that is substantially complementary to the second adapter, to generate a double-stranded member of the nucleic acid library lacking all, or a portion of, the nucleic acid analyte sequence.

2. The method of claim 1 , wherein the single-strand of the double-stranded member of the nucleic acid library comprises the first adapter, the barcode, the capture domain, the sequence that is complementary to all or a portion of the nucleic acid analyte sequence, and the second adapter, in a 5′ to 3′ direction.

3. The method of claim 2 , wherein the single-strand of the double-stranded member of the nucleic acid library further comprises a unique molecular identifier (UMI) disposed between the barcode and the capture domain.

4. The method of claim 1 , wherein the first primer comprises (i) the sequence substantially complementary to the 3′ region of the nucleic acid analyte sequence and (ii) the second restriction endonuclease recognition sequence, in a 3′ to 5′ direction.

5. The method of claim 1 , wherein the second primer comprises (i) the sequence substantially complementary to the 5′ region of the nucleic acid analyte sequence and (ii) the second restriction endonuclease recognition sequence, in a 3′ to 5′ direction.

6. The method of claim 1 , wherein the barcode is a cell barcode or a spatial barcode.

7. The method of claim 1 , wherein the ligating in step (c) and/or step (f) is performed using a ligase or using template mediated ligation.

8. The method of claim 7 , wherein the ligase is a DNA ligase, optionally wherein the DNA ligase is T4 ligase.

9. The method of claim 1 , wherein the nucleic acid library is a DNA library or a cDNA library.

10. The method of claim 1 , wherein the nucleic acid analyte sequence encodes an immune cell receptor.

11. The method of claim 10 , wherein the nucleic acid analyte sequence encodes a constant region of the immune cell receptor.

12. The method of claim 11 , wherein the nucleic acid analyte sequence further encodes a variable region of the immune cell receptor.

13. The method of claim 12 , wherein the sequence that is complementary to all or a portion of the nucleic acid analyte sequence encoding the constant region of the immune cell receptor is positioned 5′ relative to the sequence that is complementary to all or a portion of the nucleic acid analyte sequence encoding the variable region of the immune cell receptor.

14. The method of claim 12 , wherein the sequence that is complementary to all or a portion of the nucleic acid analyte sequence encoding the constant region of the immune cell receptor is positioned 3′ relative to the sequence that is complementary to all or a portion of the nucleic acid analyte sequence encoding the variable region of the immune cell receptor.

15. The method of claim 12 , wherein the immune cell receptor is a B cell receptor.

16. The method of claim 15 , wherein the B cell receptor comprises an immunoglobulin kappa light chain and wherein the variable region comprises a CDR3 of the immunoglobulin kappa light chain, or

wherein the variable region comprises or one both of CDR1 and CDR2 of the immunoglobulin kappa light chain, or

wherein the variable region further comprises a full-length variable domain of the immunoglobulin kappa light chain.

17. The method of claim 15 , wherein the B cell receptor comprises an immunoglobulin lambda light chain, and wherein the variable region comprises a CDR3 of the immunoglobulin lambda light chain, or

wherein the variable region further comprises one or both of CDR1 and CDR2 of the immunoglobulin lambda light chain, or

wherein the variable region further comprises a full-length variable domain of the immunoglobulin lambda light chain.

18. The method of claim 15 , wherein the B cell receptor comprises an immunoglobulin heavy chain, and wherein the variable region comprises a CDR3 of the immunoglobulin heavy chain, or wherein the variable region further comprises one or both of CDR1 and CDR2 of the immunoglobulin heavy chain, or wherein the variable region further comprises a full-length variable domain of the immunoglobulin heavy chain.

19. The method of claim 12 , wherein the immune cell receptor is a T cell receptor.

20. The method of claim 19 , wherein the T cell receptor comprises a T cell receptor alpha chain and wherein the variable region comprises a CDR3 of the T cell receptor alpha chain, or

wherein the variable region further comprises one or both of CDR1 and CDR2 of the T cell receptor alpha chain, or

wherein the variable region further comprises a full-length variable domain of the T cell receptor alpha chain.

21. The method of claim 19 , wherein the T cell receptor comprises a T cell receptor beta chain and wherein the variable region comprises a CDR3 of the T cell receptor beta chain, or

wherein the variable region further comprises one or both of CDR1 and CDR2 of the T cell receptor beta chain, or

wherein the variable region further comprises a full-length variable domain of the T cell receptor beta chain.

22. The method of claim 12 , wherein the method further comprises:

(h) determining (i) all or a portion of the sequence encoding the variable region of the immune cell receptor or a complement thereof, and (ii) the sequence of the barcode or a complement thereof.

23. The method of claim 22 , wherein the determining in step (h) comprises sequencing (i) all or a portion of the sequence encoding the variable region of the immune cell receptor or a complement thereof, and (ii) the sequence of the barcode or a complement thereof.

24. The method of claim 22 , wherein the nucleic acid analyte was released from a biological sample, and the method further comprises:

determining a location of the nucleic acid analyte in the biological sample using the determined sequences of (i) and (ii).

25. The method of claim 1 , further comprising generating the double-stranded member of the nucleic acid library.

26. The method of claim 25 , wherein the step of generating the double-stranded member of the nucleic acid library comprises:

contacting the nucleic acid analyte with a capture probe comprising the first adapter, the barcode, and the capture domain, wherein the capture domain binds specifically to a sequence present in the nucleic acid analyte;

extending an end of the capture probe using the nucleic acid analyte specifically bound to the capture domain as a template, thereby generating an extended capture probe; and

adding the second adapter to an end of the extended capture probe, thereby generating the double-stranded member of the nucleic acid library.

27. The method of claim 26 , wherein the capture probe comprises the first adapter, the barcode, and the capture domain in a 5′ to 3′ direction.

28. The method of claim 27 , wherein a 3′ end of the capture probe is extended, and optionally, wherein the second adapter is added to a 5′ end of the extended capture probe.

29. The method of claim 24 , wherein the biological sample is a tissue sample or a tissue section, and optionally, wherein the tissue section is a formalin-fixed paraffin-embedded tissue section or the tissue section is a fresh, frozen tissue section.

30. The method of claim 1 , wherein the nucleic acid analyte sequence is RNA, mRNA, DNA, or genomic DNA.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: GALLANT, CAROLINE JULIE; STOECKIUS, MARLON
To: SPATIAL TRANSCRIPTOMICS AB
Reel/Frame 062604/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: PFEIFFER, KATHERINE
To: 10X GENOMICS, INC.
Reel/Frame 062604/0404 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: SPATIAL TRANSCRIPTOMICS AB
To: 10X GENOMICS, INC.
Reel/Frame 062604/0520 →
Continuity (4)
Continuation 17690628 · Mar 9, 2022
Continuation PCTUS2021035211 · Jun 1, 2021
Provisional Application 63033577 · Jun 2, 2020
Related Publication 20230033960A1 · Feb 2, 2023
Cited By (47)
US 12,195,790 US 12,203,134 US 12,209,280 US 12,223,751 US 12,228,544 US 12,234,505 US 12,241,060 US 12,241,890 US 12,249,085 US 12,265,079 US 12,270,077 US 12,275,988 US 12,281,357 US 12,286,673 US 12,287,264 US 12,297,486 US 12,297,487 US 12,297,488 US 12,344,892 US 12,365,935 US 12,365,942 US 12,371,688 US 12,378,607 US 12,385,083 US 12,391,979 US 12,391,980 US 12,399,123 US 12,405,264 US 12,416,603 US 12,435,363 US 12,442,045 US 12,497,654 US 12,508,590 US 12,545,949 US 12,553,805 US 12,553,898 US 12,566,113 US 12,566,114 US 12,571,029 US 12,624,475 US 12,637,706 US 12,692,492 US 12,735,743 US 12,742,166 US 12,742,199 US 12,747,467 US 12,747,475